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A B S  TRA C T  When a  quantum of transmitter is released into a  synaptic cleft, 
the magnitude of the subsynaptic response depends upon how much transmitter 
becomes bound  to receptors. Theoretical considerations lead to the conclusion 
that  if receptor  density  is  normally  high  enough  that  most  of the  quantal 
transmitter  is  captured,  subsynaptic  quantal  responses  may be insensitive  to 
receptor  blockade.  The  effectiveness  of  receptor  blockers  in  depressing  the 
subsynaptic response should be diminished by interference with processes that 
normally dispose of transmitter, but increased if receptor density is reduced. In 
conformity  with  equations  derived  from  a  simple  mathematical  model,  the 
apparent  potency  of  (+)-tubocurarine  (dTC)  to  depress  the  peak  height  of 
miniature end-plate currents  (MEPCs)  in mouse diaphragm was substantially 
reduced by poisoning of acetylcholinesterase (ACHE) and increased by partial 
blockade  of receptors  by  immunoglobulin  G  from  patients  with  myasthenia 
gravis or a-bungarotoxin. We calculated  from the data that normally capture 
of quantal  acetylcholine  (ACh)  by receptors  is  ~75%  of what  it would  be if 
there were no loss of ACh by hydrolysis or diffusion of ACh from the synaptic 
cleft. This fraction is increased to ~90% by poisoning of ACHE. Conversely, it 
normally requires blockade of ~80% of receptors--and after AChE poisoning, 
~90% of receptors--to reduce ACh capture  (and MEPC  height)  by 50%. The 
apparent  potency of dTC to alter MEPC  time-course (after AChE  poisoning) 
and to depress responses to superperfused carbachol was much greater than its 
apparent potency to depress MEPC  height, but corresponded closely with the 
potency of dTC  to  block receptors  as calculated  from the  action  of dTC  on 
MEPC  height.  These  results  indicate  that  the  amplitude  of the  response  to 
nerve-applied acetylcholine does not give a direct measure of receptor blockade; 
it is, in general, to be expected that an alteration of subsynaptic receptor density 
may not be equally manifest in responses to exogenous and endogenous neuro- 
transmitter. 
INTRODUCTION 
Katz  and  Miledi  (1973  a)  and  Hartzell  et  al.  (1975)  have pointed  out  that 
when acetylcholine  (ACh)  is released by the motor nerve terminal and enters 
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the junctional  cleft,  a  large  fraction  of the  ACh  may  become  bound  to 
receptor.  A  simple  consequence  that  has  received  little  attention  is  that 
inactivation,  blockade, or loss of receptors should not entail a  proportional 
reduction in the response to ACh released by the nerve terminal. This arises 
because  the  ACh  molecules  in  the  synaptic  cleft  are  rapidly  partitioned, 
resulting in several possible fates. Some encounter acetylcholinesterase (ACHE) 
and are hydrolyzed, some escape by diffusion, and some become attached to 
receptor. The net effect of partial  blockade of receptors on the postsynaptic 
response  to  a  quantum  of ACh,  i.e.,  on  the  miniature  end-plate  current 
(MEPC),  must depend on the relative weights of the different probabilities 
governing this  partitioning.  For example, when hydrolysis is  removed as  a 
route of ACh disposal by poisoning of ACHE, it should require more blockade 
of receptors to produce a  given depression of the MEPCs.  Indeed, to take a 
reductio ad absurdum,  if there were no loss or escape of ACh by hydrolysis or 
diffusion  and  the  affinity of receptors  for ACh  were sufficiently high,  the 
MEPC would remain the same in size, despite an increasing receptor blockade, 
for as  long as  there remained sufficient receptors to  capture  the ACh  in  a 
quantum. It also follows that with an irreversible blockade of a high proportion 
of the postsynaptic receptors and consequent impairment of the efficiency of 
ACh capture, any further blockade of receptors by a  reversible agent should 
be more directly reflected in depression of the response to endogenous trans- 
mitter. In these experiments we have measured the effects of (+)-tubocurarine 
(dTC)  on  amplitude and time-course of MEPCs.  The apparent  potency of 
dTC is indeed altered by poisoning of AChE and by irreversible blockade of 
receptors in the same fashion as predicted. Quantitatively, the data indicate 
that  normally  most  of the  ACh  released  into  the  synaptic cleft  is  rapidly 
captured  by  receptor,  and  that  the  fraction  captured  is  higher  than  the 
fraction  of ACh  apparently  bound  to  receptors as  it  diffuses out  from  the 
synaptic cleft during the decay phase of MEPCs  (Katz and Miledi,  1973a). 
Moreover, the response of end-plates to a  grossly applied cholinergic agonist 
such as carbachol is much more readily blocked by dTC than the response to 
endogenous quantal ACh; this is compatible with equal blockade by dTC of 
receptors involved in responses to exogenous or endogenously released cholin- 
ergic agonist. 
THEORY 
Here we show that elementary theoretical considerations imply that MEPC 
height should not simply be proportional to density of functional postsynaptic 
receptors; sensitivity of MEPC height to postsynaptic blockade depends upon 
the normal efficiency  of  ACh capture by receptors. This conclusion is unaltered 
by consideration of a variety of relatively complex (and more realistic) models 
of postsynaptic  events.  The  equations  that  are  derived provide  a  basis  for 
estimating the normal efficiency  of ACh capture by receptors from observation 
of the  sensitivity  of MEPC  height  to  manipulation  of this  efficiency by 
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A  Simple Model and Its Predictions 
We will begin by considering the simplest possible model of events immedi- 
ately after release of a  quantum of ACh into the synaptic cleft, treating the 
latter as a  single homogeneous compartment in which ACh may be hydro- 
lyzed, escape by diffusion (or perhaps other mechanisms), or bind to receptors. 
The  rate  of binding  to  receptor  will  be  proportional  to  the  subsynaptic 
receptor density (R). Thus, as a  first approximation, the fraction of ACh that 
becomes bound (F) will be 
F  ---  aR/(an  +  B)  =  1/[1  +  B/(aR)].  (1) 
Here a  is  the onward rate constant  for combination of ACh with receptor, 
and  fl  is  a  constant  that  includes  the  rates  at  which  ACh  is  hydrolyzed, 
diffuses, or, perhaps,  becomes bound to sites other than activated receptors. 
On the assumption that synaptic conductance is proportional to the amount 
of ACh that is bound in such a  way as to open ionic channels (cf. Katz and 
Miledi [1973 a]), the conductance and current produced by a single quantum 
of ACh, i.e., the miniature end-plate current (MEPC) should be related to the 
receptor density in the following way: 
g  -  gmF  =  gin/[1  +  fl/(aR)].  (2) 
Here g  designates the conductance or current at the peak of the MEPC and 
gm  represents  what  this  value  would  be  if there  were  no  loss  of ACh  by 
hydrolysis or diffusion, i.e., if all the ACh became associated with activated 
receptor. It follows that if o.R is normally much more than r, so that most of the ACh 
is quickly bound, R can be considerably reduced with relatively small change in g. This is 
true either for a reversible or irreversible reduction of R. Conversely, reduction 
of fl will also have little effect on MEPC height (g)  if aR is normally much 
more than ft. The percentage increase in MEPC size that results from reducing 
fl by poisoning of AChE will be greater the less the efficiency of ACh capture 
by  receptors.  Thus,  there  are  two  methods  by  which  efficiency may  be 
estimated: 
(A) From the increase of MEPC height by AChE poisoning: 
Writing ra for fl when hydrolysis does not occur, ra for (fl -  rid) and ga and 
gd for the MEPC height before and after poisoning ACHE, then from Eq. 2 
ga/ga  =  (aR  +  ra  +  fld)/(aR  +  rid). 
Rearranging, then substituting for aR one obtains 
gd/ga  =  (rd  +  rh)/(rd  "]" flh[gJgm]).  (3) 
Thus,  when gJgm  is  reduced,  by  reversible  or  irreversible  blockade  of 
receptors,  the percentage increase of MEPC  size produced by poisoning of 
AChE should be made larger.  A  graph  of (ga/ga) -a  vs. ga should be linear, 
with an intercept at g~ =  00frd/(rh  +  rd) and the extrapolated value ofg. 
at ga/ga  --  1 should give gin. Once gra is obtained the efficiency of capture is 
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(B)  From the altered apparent potency of a  reversible receptor antagonist 
when fl  and/or  R  is  altered,  either by  poisoning AChE  or  by  irreversibly 
blocking receptors: 
On  the  assumption  that  the  reversible  antagonist  will  occupy available 
receptors to an extent that is unaffected by changes in fl or R, the degree of 
receptor blockade will be a  reproducible function of I, the concentration of 
antagonist.  For  an  antagonist  for which  the  rate  of dissociation  from  the 
receptor is slow relative to the duration of the MEPC one may write 
R  =  Ro/[1  +  f(I)], 
where I  is  the concentration of antagonist,  and  R  is  the effective receptor 
density during the time that quantal transmitter is present in the cleft. Here, 
R0 is the density of unblocked receptors in the absence of antagonist, and f(1) 
is a function of/that depends upon the mode of interaction of/with receptor. 
Only for the particular case of an antagonist that occupies receptor on a one- 
to-one  basis  is  f(I)  equal  to  //KI,  where K1  is  the  antagonist  dissociation 
constant. 
By subsitution in Eq, 2 
g/gm  =  {1  +  [1  +  f(I)]fll(aRo)} -1.  (4) 
Writing g0 for the height of the MEPC in the absence of reversible antagonist 
and gI for the height when the antagonist is present, the relative depression of 
the MEPC height by the antagonist will be related to fl and R0 as follows: 
go  =  1 +  [1  +  f(1)]fl/(a.R)o 
==  1 +  f(1) -  f(I)/[1  +  fl/(tlR0)]. 
1  +  fl/(aRo)  gx 
From Eq. 2, 
hence, 
[1  +  fll(tlRo)]-'  =  golgm, 
go/g  =  i  +  f(I)  (1  -go~g=)  =  I  +  (Ro/R-  1)  (1  -  Fo)  (5) 
f(])  ----- (go/gI-  1)/(1-  go/gm)  (5a) 
R/Ro =  [1  +  f(i)]-x  --  (go-X __gm-1)/(gi-1  _gm-~).  (5b) 
From Eq.  5,  it  is again evident that the effectiveness of the antagonist  to 
reduce transmitter  capture,  and  hence  MEPC  height  is  dependent  on  the 
initial efficiency of capture (go/gin). The particular I at which MEPC height 
is reduced by 50%, i.e., its IC50, will increase with go. When f(I) is simply I/ 
Kx,  the IC50  will  be  inversely proportional  to  1 -  go/gm. This  relationship 
might then be used to estimate gm from the graph of (IC50) -I vs. go when go 
is  varied.  However, the functional relation between I  and  f(I)  need not be 
known to estimate gm from alteration of g by the antagonist. Writing g~  and 
gl and g6'  and g['  for the MEPC heights at  two different fl and/or R  in the 
absence of antagonist and at any defined concentration of the antagonist, one PENNEFATHER AND  (~UASTEL 
has, from Eq. 5, 
and hence, 
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g6'(g~/g~ --  1) -- g'o(g6'/g~'  --  1)  ---- gm(g'o/gl  -- g~/gi').  (6) 
The  same  expression  applies  if g6  and  g6'  are  MEPC  heights  at  one 
concentration of inhibitor and gl and g~' the heights at another concentration 
of inhibitor. From this equation, a  graph of the expression on the left vs. the 
expression in brackets on the right should be linear with a  slope of gin. Once 
gm is known, use of Eq. 5a allows determination of f(I) as well as the normal 
efficiency of ACh capture. 
It should be noted that the validity ofEq. 6 depends only on (a) the validity 
of Eq. 2, i.e., that the inverse of MEPC height be linearly related to the inverse 
of the density of available receptors, and  (b)  the validity of the assumption 
that the interaction of antagonist with receptors is not influenced by changes 
in  fl  (i.e.,  by  poisoning  of ACHE)  or  by  changes  in  R  produced  by  an 
irreversible antagonist. 
More Complex Models 
The derivation of Eq. 2 represents a drastic simplification of the actual events 
that occur after discharge of transmitter into the synaptic cleft. In particular, 
it ignores (a) the dynamics of ACh association and dissociation from receptor 
during the rising phase of the MEPC,  (b)  diffusion of ACh within the cleft, 
(r  the possibility of local saturation of receptors,  (d)  cooperativity in ACh- 
receptor interaction,  and  (e)  the possibility  that  ACh  may be captured  by 
receptors that are unable to open ionic channels. We have therefore calculated 
(using  numerical  integration  of differential  equations  on  a  computer)  the 
binding  of ACh  to  receptors  and  generation  of  MEPC  with  models  of 
increasing complexity, incorporating the above factors. 
In general, we have found that when any or all the complicating factors are 
taken into account, and over a  wide range of arbitrarily chosen parameters, 
the relation between MEPC amplitude and effective receptor density always 
remains  very  close  to  that  given  in  Eq.  2.  With  variation  of R0  (partial 
irreversible blockade of receptors), variation of R  (additional blockade by a 
reversible inhibitor), and reduction of fl (poisoning of ACHE), graphs of l/g 
vs.  Ro/R  always give straight lines that meet close to Ro/R  =  0  and  1/g  -~ 
1/g~.  Fig.  t  shows  such  graphs  for  three  models.  In  Fig.  1A,  a  single- 
compartment model in which ACh combines with receptor reversibly (to form 
acetylcholine receptor [AchR]), and either diffuses away or is hydrolyzed is 
shown. The total amount of receptor is presumed to be so great that it is not 
changed  as  a  result  of combination  with  ACh.  This  model can  be  solved 
explicitly. In Fig.  1 B, an eight-compartment model in which ACh abruptly 
enters a  central compartment and then diffuses outwards is shown. In each 
compartment, it  interacts reversibly with  a  limited quantity of receptor. In 318  THE  JOURNAL  OF  GENERAL  PHYSIOLOGY  ￿9  VOLUME  78  ￿9  1981 
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FIGURE  1.  The relation between the inverse of computed MEPC  peak height 
and Ro/R -  1 is plotted for three different models of the junction:  A, B, and C. 
(A) One compartment, reversible attachment of ACh to receptor to form active 
complex, AChR*,  no receptor saturation.  (B)  Eight  concentric  compartments 
with ACh diffusing from center, interacting with receptor in every compartment 
to form AChR*--receptors can become saturated.  (C) Same model as B except 
active form of receptor is ACh2R*.  In each case the lower pair of lines  (O, Q) 
represent  calculated  points  for control conditions  and  the upper pair of lines 
(I-3, I)  values calculated using the same parameters except receptor density (R0) 
reduced to 25 of  control. Ro/R is presumed to be varied by a reversible antagonist 
with high affinity for the receptor. The open symbols represent values calculated 
assuming  hydrolysis  of transmitter  in  the  cleft  (ACHE  intact); filled  symbols 
represent values calculated with transmitter loss from the cleft only by diffusion, 
i.e., corresponding to AChE poisoned. The abscissa is Ro/R -  1 rather than Ro/ 
R  because values of Ro/R <1  cannot be arrived at by altering R. Note that in 
the case of an inhibitor  (I) that blocks receptors on a one-to-one basis Ro/R - 
1 =  I/KI, where KI is the dissociation constant of the inhibitor-receptor complex. PENNEFATHER AND Q UASTEL  Receptor Blockade and MEPCs  319 
this case it.is assumed that attachment of only one ACh molecule is sufficient 
to activate receptor.  Fig.  1 C shows the same as Fig.  1 B except that two ACh 
molecules are needed to activate  receptor.  In  this  last  model, which,  of the 
three, is the only realistic one for the neuromuscular junction  (cf. Rosenberry 
[1979]; Dreyer et al.  [1978]; Sheridan and Lester [1977]), each ACh molecule 
interacts with one subunit of the receptor and an isomerization occurs, leading 
to an open ionic channel, only when both subunits are occupied. This stabilizes 
the  binding  of ACh  so that  the dissociation  rate  becomes equivalent  to the 
rate of channel closing. 
The  latter  two  models  were  essentially  similar  to  those  considered  by 
Rosenberry (1979) except for the employment of more compartments  for the 
simulation  and  with  the  last  model  calculated  MEPCs were essentially  the 
same as those of Wathey et al.  (1979). The values shown in Fig.  1 C are from 
model MEPCs that  roughly approximated  true MEPCs, and the parameters 
used were close to those employed by Wathey et al. (1979); the receptor target 
radius  was  1.1  /~m,  i.e.,  any transmitter  diffusing >1.1  ~m  from its point  of 
origin  was  assumed  lost  to the system.  In  this  case,  the  rate  constants  were 
such that binding rather than isomerization was rate-limiting.  However, very 
similar  plots  were  obtained  with  models  in  which  isomerization  was  rate- 
limiting (of. Adams [1980]), and, in general, the form of plots such as those in 
Fig.  1 C was quite insensitive to the parameters that were chosen, over a  very 
wide range. In particular it may be noted that there was little effect of altering 
the rate constants of the first ACh receptor interaction,  provided these were 
sufficiently rapid,  i.e.,  the extent of binding  of ACh  in a  transitory  form to 
receptor had little influence. With all the models tested the increase of MEPC 
height produced by eliminating AChE always conformed closely to Eq. 3, i.e., 
the percentage  increase of height  was made larger when MEPCs were made 
smaller by reduction of receptor density, and plots ofga/gd VS. ga were linear. 
However, derived values offl/(flh + fld) did not correspond in any simple way 
to  the  relative  importance  of hydrolysis  and  diffusion  in  disposing  of the 
transmitter,  with models incorporating cooperativity. Moreover, the extrapo- 
lated maximum possible MEPC height, gin, was not the same as the number 
of  transmitter  molecules  divided  by  the  number  necessary  to  activate  a 
receptor.  Typically,  for models  in  which  two ACh  molecules are  needed  to 
open  a  channel,  gm  (by  extrapolation)  was  at  most  3,500  channels,  for  a 
quantum  containing  10,000  molecules of ACh,  (Hartzell  et  al.,  1975).  This 
difference arises because any set of parameters  that  can  produce an  MEPC 
that  is rapidly  rising  but  not  overly prolonged  relative  to channel  duration 
also implies that  at  the time of the MEPC peak there is still  a  considerable 
quantity of ACh attached to receptor in a closed conformation, i.e., AChR or 
ACh2R  in  a  form not  yet isomerized  to the active form.  Values of g/gm  are 
close to, but not synonymous with, the fraction of released transmitter  that  is 
bound to activatable receptors at the peak of the MEPC. 
We have also calculated,  with the above models, the net effect on MEPC 
height  (and time-course)  of (a)  a  competitive antagonist  that  dissociates very 
rapidly  from  the  receptor,  and  (b)  what  would  be  expected  if there  were 320  THE  JOURNAL  OF  GENERAL  PHYSIOLOGY  ￿9  VOLUME  78  ￿9  1981 
transmitter-binding  sites that were not activatable receptors. In general, either 
modification  made  little  difference.  Provided  the  affinity  of  receptor  for 
antagonist is sufficiently high that at equilibrium most of the total antagonist 
in the cleft is attached  to receptors, the behavior is virtually identical to that 
found  with  a  slowly  dissociating  (or  irreversible)  antagonist.  This  occurs 
because  no  substantial  displacement  of antagonist  from  receptor  can  take 
place without a large consequent increase in free antagonist in the cleft. In the 
case of extra  binding  sites  for ACh,  if the  rate  constant  of dissociation  was 
made rapid relative to dissociation of transmitter  from the active form of the 
receptor, the net effect was equivalent to an increase offl in Eq.  1. In the case 
of binding  sites  that  interact  with  transmitter  and  antagonists  in  the  same 
way as receptors but do not act to open channels  (i.e., "silent" receptors) the 
net effect was merely a constant fractional reduction in the MEPC. 
It  may  also  be  remarked  that  with  all  these  models  one-half-maximal 
reduction  of the  time  constant  of the  decay phase  of MEPCs  (after AChE 
poisoning)  by receptor blockade was associated with one-half-maximal  occu- 
pation of receptors by the blocker (see Eq. 8, below). 
Still More Complex Models 
In  the  models  already  considered,  the  number  of ACh-binding  sites  on  a 
receptor was the same as the number  of ACh  molecules required  to initiate 
the conformational  change associated with opening of a  channel,  and in the 
presence of an antagonist,  the receptor was either blocked or unblocked. It is 
possible, however, that  the number of binding sites is more than the number 
of ACh  molecules  needed  to  activate  them,  and  that  an  antagonist  may 
combine with one or more of these sites without entirely excluding activation 
of the  receptor  by  ACh.  In  such  a  case,  one  loses  the  simple  distinction 
between blocked and unblocked receptors.  Numerical  evaluation of the con- 
sequences of such  models  is extremely slow because of the  large  number of 
receptor species in each compartment  and the many ways in which coopera- 
tivity  may  be  specified.  Nevertheless,  from  those  cases  for  which  we  have 
created models, we feel that  it can be stated that  the model complexity does 
not  result  in  behavior substantially  different  from  that  of simpler  models  in 
that  Eqs. 2-6 remain applicable. 
METHODS 
All  experiments  were performed on  mouse hemidiaphragms,  mounted  on  Sylgard 
(Dow Coming Corp., Midland, Mich.). End-plate regions were directly superperfused 
(Cooke and Quastel,  1973) with solution bubbled with 95% O2-5% CO2, at 25-27~ 
The standard solution used had the following composition: Na  + (150 mM), Ca  ~+ (2 
mM), Mg  3+ (1 mM), K + (5 mM), HCO~" (24 mM), H2PO; (1 mM), NO~ (135 mM), 
glucose (11 raM). NO~ was employed instead of Cl-, to improve the signal-to-noise 
ratio of the MEPCs (Linder and Quastel,  1978). In addition,  tetrodotoxin  (Sankyo 
Co. Ltd., Tokyo; 2 ￿  10  -s g/ml) was used to eliminate the occasional muscle twitching 
that  otherwise occurred when  miniature  end-plate potentials  (MEPPs)  were made 
large by inhibition of ACHE. In many of the experiments, [K  +] was raised to 10 mM, 
to increase MEPP frequency and therefore permit faster acquisition of data. Control PENNEVATHER AND QUASTEL  Receptor Blockade and MEPCs  321 
experiments showed  that  neither  this nor the substitution  of NO3  for CI- had  any 
effect on MEPC time-course or amplitude (Linder and Quaste[,  1978). 
Voltage Clamp 
The techniques employed for the two-electrode point vohage-clamp were essentially 
conventional  (Takeuchi and Takeuchi,  1959)  using microelectrodes filled with  3 M 
KCI. That both electrode tips were located in the same muscle fiber and close to an 
endplate  was judged  from the  appearance  on  the  records  from both  electrodes  of 
identical, fast-rising MEPPs.  During operation of the voltage clamp, the total gain of 
the feedback loop was usually ~4,000:1  (direct current-1  kHz), and there were never 
any detectable voltage signals corresponding to the MEPCs recorded by the current 
monitor.  Membrane potential was always maintained within  1 mV of the holding 
potential. 
Recording 
To improve the signal-to-noise ratio of MEPCs and therefore to permit the computer 
to identify and store MEPCs without selection as to amplitude  (except for the very 
smallest  population--&.  Cooke and  Quastel  [1973];  Kriebel and Gross [1974]),  the 
signal  from  the  current  monitor  was  put  through  a  running-average  (modified 
Paynter)  filter;  filters constructed  for averaging times of 0.1  ms, 0.2  ms, and 0.5  ms 
were used  in conjunction  with analog-digital  (A-D)  conversion at  frequencies of 10 
kHz, 5 kHz, and 2 kHz, respectively. 
Before  going  to  the  A-D  converter  of a  PDP-12  computer  (Digital  Equipment 
Corp., Maynard,  Mass.)  the current  signal was amplified and  filtered further with 
simple resistance-capacitance  filters set  at 0.1  Hz  (lower limit)  and either 3  kHz,  1 
kHz, or 0.3 kHz (upper limit). In nearly all experiments, the upper limit was set at 3 
kHz or  1 kHz--the  1-kHz setting reduced the noisiness of the signal but introduced 
a need for appreciable digital correction of the records (see below). The 0.3-kHz filter 
quite  severely distorted  the rising phase of MEPCs,  but was occasionally useful  for 
the recording of MEPCs that would otherwise have been too small to be identified as 
MEPCs by the computer program. 
Recording of MEPCs 
MEPCs  were  recorded  on  digital  tape  using  a  PDP-12  computer  programmed  to 
identify  MEPCs  as abrupt  transients  larger than  a  preset  threshold.  The program 
excluded  any  MEPCs  preceded  by another  MEPC  within  ~50  ms or  followed by 
another  MEPC  during  its  decay  phase.  Subsequently,  the  records  were  examined 
visually to  identify  artifacts,  multiple  MEPCs  (recognized  from steps  in  the  rising 
phase), and "unusual" MEPCs  (Cooke and Quastel,  1973;  Kriebel and Gross,  1974), 
which  were subsequently excluded  from averages. Also excluded  were any MEPCs 
that appeared to be superimposed on a baseline with a significant trend. 
Averaging of MEPCs 
The major problem encountered in averaging MEPCs (at least 25 and usually ~40 in 
each  group)  was  to  establish  a  time reference for each  signal  in  such  a  way as  to 
superimpose the steepest (i.e., initial) portion of the rising phases as closely as possible. 
The method finally adopted was to find the point of maximal cross-correlation with 
a ramp function  (0,0,...0,  1, 2). This gave MEPC averages with total rise time slightly 
less than, and peak amplitude slightly greater than, those obtained by using either of 
two other fairly satisfactory criteria for definition of the time reference: (a) the pair of 322  THE  JOURNAL  OF  GENERAL  PHYSIOLOGY  ￿9  VOLUME  78.  1981 
points in the rising phase with maximum difference, or (b)  the group of points (three 
or four) in the rising phase with maximum variance. 
The height,  rate of rise,  and rate of decay of an MEPC  average were essentially 
identical to the averages of the same parameters of individual MEPCs, except where 
AChE  had been poisoned,  in which  case MEPCs  varied greatly in  time-course and 
time-course and height were positively correlated (Hartzell et al.  1975). 
Calculation of MEPC Parameters 
All calculations were done on the PDP-12 computer directly from the MEPCs and/or 
from averages of MEPCs stored on digital  tape. Always, before further calculations 
were made, the baseline  (an average of 25 points before the rise of the MEPC)  was 
subtracted  and  all points  were corrected  for the high-frequency filtering employed 
during recording, using either of two algorithms: (a) replacement of each value Xi by 
(Xi -  Z.Xi- 1)/(1  -  Z), where Z ~  exp (--At~TO, At is the time between samples, and 
~'r is the time constant corresponding to the high frequency filter, or (b) replacement 
of each value Xi by Xi +  ~'f(Xi + 1 -  Xi- 1)/(2At). The result of the second method was 
about equivalent to that of the first followed by a running two-point smoothing and 
was employed when parameters were to be determined on individual MEPCs.  With 
individual MEPCs recorded after poisoning ACHE, the height was defined as the peak 
average of three sequential  points;  with these MEPCs, time constants of decay were 
sufficiently  long  relative  to  the  frequency  of A-D  sampling  that  the  MEPC  peak 
corresponded to a plateau of at least three nearly equal points. 
Data were accepted as being from a  focally placed clamp only if the maximum 
rate of rise of the average of the MEPCs in a sequence, corrected for filtering, was at 
least two-thirds of the peak height in 0.2 ms, when MEPCs were sampled at  10 kHz, 
or  80%  of peak  height  in  0.4  ms,  when  sampling  was  5  kHz.  When  AChE  was 
poisoned, the rise time of MEPCs was somewhat prolonged; MEPCs were recorded at 
5 kHz and were accepted as focal if two-thirds of peak height was achieved in 0.4 ms. 
These limits excluded ~25% of records that had been tentatively accepted as "focal" 
at the time of recording. 
The rate of decay of MEPCs was determined by a least-squares procedure applied 
to points of the MEPC  lying between e -~  and e -1"5 of the MEPC  peak amplitude. 
The lack of bias of this procedure was verified by applying it to computer-generated 
series of points following predetermined rates of exponential decay with added white 
or filtered noise of various magnitudes. 
Responses of End Plates to Carbachol 
In some experiments carbachol  was  applied  (by local superperfusion)  to endplates 
and the ensuing depolarization (A V) measured. Experiments were limited to junctions 
that  gave  a  prompt  response  to  carbachol  and  returned  to  control  value  upon 
withdrawing carbachol. To correct for nonlinearity of the postsynaptic response, the 
following equation was used 
--AV 
AG/G =  Vm +  AV exp [.0075(80  +  Vm +  AV)]. 
Here  Vm  is  the  control  membrane  potential.  This  equation  corresponds  to  the 
correction of Martin (1955) with the assumption of a transmitter equilibrium potential 
of 0  (Linder and Quastel,  1978)  and with the addition of a term to adjust for voltage 
sensitivity of the  mean duration  of the  ionic conductance  channels  (Anderson  and 
Stevens,  1973);  it  was  assumed  that  channels  opened  by carbachol  have the  same PENNEFATtlER AND  QUASTEI.  Receptor Blockade and  MEPCs  323 
voltage sensitivity as those opened by ACh. In principle, the result of this correction 
should be proportional  to the conductance that would have been measured if the 
muscle fiber had been clamped at -80 mV. 
RESULTS 
Preliminary Observations 
The theoretical treatment presented above made several predictions capable 
of experimental verification:  (a) The apparent potency of a  slowly reversible 
antagonist  should be reduced by poisoning of acetylcholinesterase (ACHE), 
and increased by irreversible blockade of receptors (Eq. 5).  (b) The increase of 
MEPC height produced by poisoning of AChE should increase when MEPCs 
are made small by either a  reversible or irreversible receptor blocker (Eq. 3). 
(c)  Eq.  6  should apply.  It was therefore necessary to find agents capable of 
producing  uncomplicated AChE  poisoning,  and  reversible  and  irreversible 
receptor blockade. 
For poisoning of AChE we found the irreversible agent paraoxon  (4 #M 
applied for a  period of 4 min) to be suitable;  this yielded MEPCs prolonged 
in  time-course and  no  further prolonged  by  application  of Prostigmin  (or 
more paraoxon), and that were unchanged for the duration of an experiment. 
Frequency of MEPCs was increased about twofold, and higher concentrations 
or more-prolonged exposure to paraoxon caused muscle contracture presum- 
ably related to  partial  depolarization  of muscle fibers  (cf. Laskowski et  al., 
[ 1975];  Laskowski and Dettbarn [ 1979]).  Prostigmin itself we found to be only 
slowly reversible and to give no practical advantage. 
As  a  reversible  competitive  inhibitor  we  chose  (+)-tubocurarine  (dTC), 
since the dissociation constant of the receptor dTC complex is known to be 
~100  nM  (Lu,  1970;  Waud et al.,  1973).  Since the "concentration" of ACh 
receptors  is  ~1  mM  (cf.  Wathey  et  al.  [1979]  and  Discussion)  the  great 
majority of dTC  molecules in  the synaptic cleft at  concentrations <<1  mM 
must  be  attached  to  receptors.  Moreover,  dTC  is  known  not  to  have  an 
appreciable local-anesthetic-like action at concentrations <1  /tM  (Katz and 
Miledi,  1978;  Colquhoun et al.,  1979).  Preliminary experiments showed that 
the reduction of MEPC amplitude produced by superperfusion with dTC was 
maximal within a  few minutes. At <--0.5 ~M dTC we could find no alteration 
of voltage sensitivity of MEPCs and no alteration of MEPC time-course not 
attributable simply to receptor blockade. 
For effectively irreversible blockade of receptors, our initial choice was a- 
bungaratoxin  (a-BuTX)  (Chang  and  Lee,  1963;  Katz  and  Miledi,  1973b; 
Magleby and Terrar,  1975),  which almost certainly has the same binding site 
as ACh (Colquhoun and Rang, 1976).  However, superperfusion with a-BuTX 
produced very uneven blockade; MEPCs at different  junctions varied between 
normal in size and nearly invisible. Injection of mice with a-BuTX was rather 
unpredictable  in  effect, giving either too  little  or too  much blockade.  The 
results with a-BuTX shown below are from one diaphragm,  from a  mouse 
injected with a-BuTX, where it was possible to record uniformly small MEPCs 
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As an alternative to ~x-BuTX we tried injection of mice with immunoglob- 
ulin G  (IgG) from patients with myasthenia gravis, which had been reported 
to give rise to MEPPs of about one-half normal size (Toyka et al.,  1975);  it 
was found that after repeated daily injections for a  few days (from a  sample 
given to us by Dr. D. B. Drachman) MEPPs and MEPCs in mouse diaphragms 
were uniformly moderately reduced in  size  and  responded  to  poisoning of 
AChE  or  dTC  much  as  predicted  for  an  irreversible  receptor  blockade. 
However, the rate of decay of MEPCs after AChE poisoning was not as fast 
as in MEPCs reduced to a similar height by dTC (Pennefather and Quastel, 
1980).  This was interpreted as indicating some continued ability of blocked 
receptor to bind ACh, because adding dTC brought the rate of decay to the 
same  limiting rate as  observed with  dTC  in  control  diaphragms,  and  it  is 
known that the IgG binding to receptor does not necessarily preclude binding 
of a-BuTX (Lindstrom and Lambert,  1978;  Mittag et al.,  1978).  As pointed 
out in Theory, such transmitter binding does not negate the applicability of 
Eq. 2, provided the complex is short-lived. 
Modification of MEPCs by Receptor Blockade and AChE Poisoning 
Table  I  lists  the mean amplitudes and time constants of decay of MEPCs, 
recorded  at  -80  mV,  in  control  diaphragms,  diaphragms  from  animals 
TABLE  I 
MEPC AMPLITUDE, "TIME CONSTANT" OF DECAY, AND SENSITIVITY TO 
(+)-TUBOCURARINE: MODIFICATIONS BY POISONING OF ACHE, IgG FROM 
MYASTHENIA PATIENTS, AND a-BuTX 
IgG from myastbenia patients 
Untreated  2 d  4 d  ct-BuTX (5/~g i.v,) 
MEPC amplitude 
Control  4,034.0.06  nA (119)  3.11+0.14  nA (11)  2,174.0.08  nA (8)  2.364"0.13  nA (11) 
After paraoxon  4.674"0.13  nA (24)  3.904"0.13  nA (7)  3,064"0.19  nA (9)  3.124"0.12  nA (13) 
MEPC  "time constant" 
Control  1.134"0.02  ms (119)  1.024"0.03  ms (11)  0.964"0.04  ms (8)  0.854"0.03  ms (11) 
After paraoxon  4.174"0.17  ms (24)  3.864"0.25  ms (7)  3.714"0.11  ms (9)  3.314"0.17  ms (13) 
IC50 for (+)-tubocurarine 
Control  1864"9  nM  1074"32  nM  734" 17 nM  -- 
After paraoxon  3394"26 nM  186:t:7  nM  1094"9  nM  1094"4  nM 
All values +  SEM.  Number of junctions  in parentheses.  Holding potential,  -80  inV. 
pretreated with IgG from myasthenia patients, and in a  diaphragm from an 
animal pretreated with a-BuTX, in each ease before and after poisoning of 
AChE  by  paraoxon.  In  conformity with  the  findings  of Katz  and  Miledi 
(1973a  and  1978),  Magleby  and  Terrar  (1975),  and  Mallart  and  Molg6 
(1978), presumptive receptor blockade by dTC, a-BuTX, or IgG from myas- 
thenia patients caused acceleration of the decay of MEPCs both before and 
after treatment with paraoxon. There were also other effects on time-course, PENNEFATaER AND  QUASTEL  Rr  Blockade and MEPCs  325 
produced by all  three agents, consisting in slight prolongation of the rising 
phase and alteration of the falling phase to approximate more closely a simple 
exponential decay. These findings will be described in detail in a subsequent 
paper. 
The increase in MEPC amplitude produced by AChE poisoning in control 
diaphragms was  16 __+ 4%.  The same average value was obtained from five 
junctions, at each of which it was possible to record MEPCs before, during, 
and  after  application of paraoxon.  This  value is  close to  that  reported for 
AChE  blockade in  snake  (Hartzel  et  al.,  1975)  and  rat  (Colquhoun et  al., 
1977).  This result in itself suggests that normally capture of transmitter by 
receptors is nearly complete (cf. Hartzell et al. [1975])--only then can blockade 
of hydrolysis have little effect. In terms of Eq.  1 (Theory), poisoning of AChE 
is tantamount to reduction of fl; a  small action on F  in the control situation 
indicates that normally aR is substantially more than ft. In the "myasthenic" 
diaphragms AChE poisoning caused somewhat greater increases in  MEPC 
size (25 -  6% for 2-d treatment, 43 -t-  10% for 4-d treatment). The same was 
true for the diaphragm treated with a-BuTX  (32  _  9%), and the effect of 
AChE  poisoning to  increase MEPC  height was  also enhanced by  receptor 
blockade by dTC (Fig. 2 A). 
lncrease of MEPC Amplitude by AChE Poisoning 
Fig.  2 B  and  C shows graphs of the increase of MEPC height produced by 
poisoning of AChE  with  paraoxon,  at  various  concentrations of dTC,  in 
control diaphragms and in diaphragms from animals treated with a-BuTX or 
with  IgG  from  myasthenia patients. Also  included  here  are  data  from  a 
diaphragm from an animal treated for 3 d with IgG from myasthenia patients; 
in this diaphragm no recordings were made with added dTC. In all cases the 
percentage increase of MEPC height was greater when MEPCs were made 
smaller by receptor blockade and the effect was independent of whether the 
MEPCs were made small  using reversible blockade by dTC, or irreversible 
blockade by a-BuTX or IgG from myasthenia patients, or a  combination of 
both. The inverse plots (graphs of control MEPC height divided by MEPC 
height after paraoxon vs. control height) show a good fit to a straight line, in 
conformity with Eq.  3.  The intercept on the oridinate gives a  value of fld/ 
(rid  +  fib)  of 0.46;  from  computer  simulation  of MEPCs  (Theory),  this 
intercept does not necessarily give the relative importance of diffusion and 
hydrolysis in disposing of transmitter. The line gives, by extrapolation, the 
value ofg at which poisoning of AChE would produce no further increase of 
MEPC height  (i.e.,  gin);  this is  5.1  ---- 0.6 nA (at  -80  mV, i.e., 64 :l:  7 nS). 
Given  that  a  single channel has  a  conductance of 20-25  pS  (reviewed by 
Colquoun, 1978)  this corresponds to the activation of ~3,000 channels. If this 
value for gm is taken to correspond to 100% uptake ofquantal ACh by receptor 
(Theory),  then  the  fraction that  becomes bound to  receptor normally and 
after the various treatments can easily be calculated; the data indicate that, 
under  normal  conditions,  79%  of the  ACh  in  a  quantum  is  captured  by 
receptor, whereas after AChE is inhibited, 92% is captured. A 
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FIGURE 2.  (A) Bar diagram showing heights of MEPCs (at -80 mV) recorded 
before and after poisoning of AChE by paraoxon. Within each bar, the broken 
line below the top of the bar indicates the height before poisoning of ACHE. In 
control diaphragms (Con) and in diaphragms from mice previously injected with 
~-BuTX (ot-BUTX)  or IgG from myasthenia patients (Myasthenic IgG), with no 
dTC and with 0.1 ~M dTC, and also with 0.4 ~M dTC in control diaphragms 
only. Number of junctions is shown in parentheses. Note that the percentage 
reduction in MEPC height by dTC was  increased by a-BuTX or IgG from 
myasthenia patients and reduced by poisoning of ACHE. Bars, +  SEM.  (B) 
Enhancement of MEPC height by poisoning ACHE. Plot of  ratio of height after 
paraoxon (gd) tO height with AChE intact (g.) vs. height with AChE intact (ga) 
at various concentrations of dTC. (0), control diaphragms; (1), 4-d IgG from PEm~EFATHER AND QUASTEL Receptor Blockade and MEPCs  327 
Modification of MEPC Amplitude by (+)- Tubocurarine 
As  already shown  in  Table  I  and  Fig.  2,  the apparent  potency of dTC  in 
reducing MEPC height was reduced by poisoning of AChE and enhanced by 
irreversible receptor blockade by a-BuTX and IgG from patient with myas- 
thenia. Fig. 3 shows a  graph of all the data plotted according to Eq. 6; each 
point is derived from averages of MEPC size with and without dTC or at two 
different levels of dTC, and with two different starting levels of MEPC height 
(produced by poisoning of ACHE, and/or pretreatment with a-BuTX, or IgG 
from myasthenia patients). Despite some scatter, the points (44 in all) fit well 
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FXOURE 3.  Plot of[g~'(g~lg~-  l)--g~(g6'/g[' -  1)] vs. (g~lg~--g~'lg~'),  where 
the subscripts 0 and I indicate either without and with dTC or two different 
levels of dTC, and the superscripts indicate any two different conditions (control, 
AChE poisoned, a-BuTX, IgG from myasthenia patients). In theory, all points 
should fall on a straight line through the origin with a slope of gin. The line is 
drawn by least-squares fitting (intercept, 0.01 •  0.08; slope, 5.35 •  0.17 nA). 
to a  straight line that passes through the origin (intersect on abcissa -- -0.01 
___  0.08)  with  a  slope,  corresponding to gin, of 5.35  +-- 0.17  nA.  This  is  not 
significantly different from the value of gm estimated from the graph in Fig. 
2C. 
Once gm is known, it is in principle possible to determine the relationship 
between concentration of dTC and f(I), since from Eq. 5 
f(I)  ---- (go~g, --  1)/(1  -- go/gm). 
patients with myasthenia; (V) 2-d IgG from myasthenia  patients; (A) 3-d IgG from 
myasthenia patients;  (￿  a-BuTX. (C) Same data as in  (B), plotted inversely 
(see Eq. 3, Theory). Line drawn by least-squares fitting; extrapolated intercept 
at ga/ga  --  1 gives an estimate of gin. 328  THE  JOURNAL  OF  GENERAL  PHYSIOLOGY  ￿9 VOLUME  78  ￿9 1981 
Thus,  from  each  observation  of MEPC  size  at  a  given  I  (and  the  value 
when I  =  0)  a  value for f(I)  is obtained.  Fig.  4  shows  the relation between 
calculated f(I) and [dTC] for the data obtained in control diaphragms, before 
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FIaURE  4.  Log-log plot of f(/)  (see text) vs. concentration of dTC. Data from 
control diaphragms  before (O)  and  after poisoning of AChE  (0).  Bars show 
SEM (in one direction only for most points, to avoid overlap). In each case f(I) 
was calculated from observed MEPC heights in the absence (go) and presence 
ofdTC (gl), from Eq. 5, taking 5.35 +  0.17 nA as the value of gin. Most of the 
SE is related to uncertainty in (1  -  go]gm). The solid line is drawn with a slope 
of unity, corresponding to proportionality between f(/) and  [dTC]. The other 
lines show theoretical curves expected if two dTC molecules can bind to receptor. 
Dashed line, equal affinity for dTC at both sites; i.e., KI  ==  /(2  =  0.14 #M. An 
almost identical curve is obtained with K1 --- 0.1 #M, K~ =  0.2 #M. The other 
dotted line is for Kx =  0.05/~M and K~ =  1 #M;  higher ratios of K2:Ka allow 
lower values of f(/) at 0.8 #M dTC and, therefore, better fit to the data. 
and after poisoning of ACHE, with [dTC] between 40 and 800 nM. This graph 
suggests  simple  proportionality  between  f(I)  and  /,  as  expected  if there  is 
simple one-to-one binding of dTC to receptor. However, previous observations 
on  the  blockade  of responses  to  cholinergic  agonists  suggest  a  one-to-one PENNEFATHER  AND  QUASTEL Receptor Blockade and MEPCs  329 
competition of dTC with ACh, of which probably two molecules interact with 
receptor to  open  an  ionic  channel  (Discussion).  On  this  basis,  one  would 
expect  that  dTC  can  attach  to  either of two subunits  of the receptor and 
therefore that the fraction of receptors free of at least one dTC molecule would 
be  given  by  1/(1  +  //KI)2;  this  would cause an  upward  curve  (and  slope 
greater than unity) in the graph in Fig. 4.  Whatever the model chosen, the 
data indicate that at  100 nM [dTC], at least 65% of receptors are effectively 
blocked; at this concentration of dTC MEPC height is reduced by 36% when 
AChE is intact and by 28% when AChE is poisoned (Fig. 2, Table I). 
In conformity with a linear relation between f(I) and [dTC], the depression 
of MEPC peak amplitude produced by varied concentrations of dTC in every 
case fitted a  linear relation between the inverse of MEPC height  (g-l)  and 
[dTC].  This  is  shown  in  Fig.  5A  for  the  control  and  4-d  "myasthenic" 
diaphragms, before and after treatment with paraoxon. The slope of the line 
relating g-1 and [dTC] was decreased by poisoning of AChE and increased in 
the "myasthenic" diaphragms, and all lines appear to meet in a  region close 
to  [dTC]  ---- -40  nM and g-1  _  0.2,  i.e., gm ---- 5  hA.  In Fig.  5 B  and  C  are 
shown the values of IC50  for dTC, derived from least-squares fitting to the 
lines in Fig. 5 A (as the ratios of intercept to slope), plotted vs. go. In conformity 
with Eq. 5 a, the IC50 increases with reduction of go (Fig. 5 B) and the graph 
of (IC50) -1 vs. go fits a straight line (Fig. 5 C), confirming that Eq. 5, with f(I) 
set proportional  to/,  provides a  good description of all the data;  data from 
the diaphragms previously treated with 0t-BuTX and for 2 d  with IgG from 
myasthenia patients are also included here. By extrapolation, 50% of receptors 
were blocked at [dTC] =  40 +_ 2 nM, and gin, the apparent maximum possible 
value for g, is 5.04 _  0.26 nA. Recalculations using the new estimate of  gin did 
not change the linear relation between f(I) and [dTC] as shown in Fig. 5. 
Modification  of MEPC Time-Course by Receptor Blockade 
Katz  and Miledi  (1973a)  pointed out that dTC should and does accelerate 
the decay of MEPCs  after poisoning of AChE by increasing the fraction of 
ACh in the synaptic cleft that is not bound to receptor and is therefore free to 
diffuse; they used this phenomenon to estimate the fraction of ACh bound to 
receptor during the decay phase. Following their argument, the rate of decay 
of MEPCs will be proportional to the fraction of ACh not bound to receptor 
(1  -  P)  at  the time when the decay rate  is measured, and  to  the rate of 
diffusion (D) of unbound ACh from the cleft, i.e., 
I  "-I  --  D(1 -  P), 
where "r is the MEPC time constant. It follows that 
~'/70 =  (1 -  P0)/(1  -  P),  (7) 
where 1"0 is the control time constant and P0 is the proportion of ACh in the 
cleft bound to receptor during the decay phase of the control MEPC.  With 
the same simplifying assumptions as used by Colquhoun et al. (1977), namely, 
(a) that each of the binding sites buffering ACh in the cleft usually binds only 330  THE  JOURNAL  OF  GENERAL  PHYSIOLOGY ￿9 VOLUME  78"  1981 
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FIGURE 5.  (A) Graphs of the inverse of MEPC amplitude vs. concentration of 
dTC: (O) control diaphragms, (0) control diaphragms after paraoxon, (U]) and 
(11) diaphragm from mouse injected 4 d  (once per day) with 0.1  ml IgG from 
patients with myasthenia, before and after paraoxon, respectively. Note resem- 
blance of graphs to those in Fig.  1; straight lines meet at [dTC] =  40 nM. SE 
bars are shown only where greater than symbols. Lines drawn by least-squares 
fitting. (B and C) Graphs of IC50 for dTC vs. MEPC height in absence of dTC. 
Symbols as in A plus:  (V)  2-d IgG from myasthenia patients, after paraoxon, 
(~7) 2-d IgG from myasthenia patients, (￿  a-BuTX, after paraoxon. The latter 
two points are nearly superimposed. (B) Linear plot; (C) plot of inverse of ICS0 
vs. initial MEPC height; the line, drawn by least-squares fitting, gives inverse of 
KI for dTC (if dTC molecule blocks receptors on a one-to-one basis) and gm at 
intersects on ordinate and abscissa, respectively. 
one  ACh  molecule or  dTC  molecule;  (b)  binding  and  dissociation  of ACh 
occur sufficiently rapidly so that there is effective equilibrium at all times;  (c) 
there is no saturation of these receptors by ACh; and (d) the concentration of PENNEFATHER  AND  O~UASTEL  Receptor Blockade and  MEPCs  331 
ACh is insufficient to alter binding of dTC, one may write 
[ACh]/[AChR]  -- Ka/R 
R  =  Ro/(1  +  I/Kz) 
P  --  [AChR]/([ACh]  +  [AChR])  --  1 +  1 + 
e0\  ' 
where R0 is the receptor concentration in the absence of antagonist. Combining 
this with Eq.  7, one obtains 
~"  ----- ~'o[1 --P0/(1  +  KI/I)].  (8) 
Thus,  the  effect of dTC  to  accelerate  decay of MEPCs  after  poisoning  of 
AChE  should  give  a  measure  of the  dissociation  constant  (Kx) for  dTC  of 
those sites involved  in  binding  ACh  during  the  decay phase  of the  MEPC. 
The graph in Fig. 6 shows averages of time constant determined on individual 
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FIGURE 6.  Reduction  of time  constant  of decay  of MEPCs  by  dTC  after 
poisoning of ACHE, in control diaphragms. Note that the effect of dTC is nearly 
maximal at 0.4 #M. Line drawn on basis of nonlinear least-squares fitting. The 
one-half-maximal effect of dTC is at 53:1:17 nM. 
MEPCs  plotted  vs.  [dTC];  the  curve  is  drawn  according  to  Eq.  8  with 
parameters  derived  by nonlinear  least-squares  fitting  to  this  equation.  The 
best fitting value of K1 for dTC is 53 +  17 nM. The apparent fraction of ACh 
in the cleft bound to receptor in the absence of receptor blockade (P0) is 0.43 
+  0.03. 
Models of postsynaptic events described in Theory that  incorporate coop- 
erativity in ACh and/or  dTC  binding to receptor also predict that  the time 
constant  of MEPCs,  when  AChE  is  poisoned,  will  be  reduced  to  halfway 
between control  and  minimum  (when  binding  is zero)  when  the  density of 332  THE  JOURNAL  OF  GENERAL PHYSIOLOGY ￿9 VOLUME  78  ￿9 1981 
binding sites is reduced by one-half. The data show that  this occurs in  the 
neighborhood of 40-100  nM.  Whatever  the  intricacies of dTC  interaction 
with  the receptor(s)  (i.e., whether or not  assumption a  above is  valid)  it  is 
evident that at  100 nM dTC the MEPC time constant was at least one-half- 
maximally reduced, although the height of the same MEPCs was reduced by 
only 28% (see Table II). 
Blockade of Postsynaptic Response to Carbachol by dTC 
To obtain another independent estimate of the receptor blockade produced 
by dTC, on the tentative assumption that all postsynaptic receptors have the 
same affinity for dTC, we employed superperfusion of the end-plate region 
with carbachol in the absence and presence of dTC. 
TABLE  II 
INHIBITION OF RESPONSES TO SUPERPERFUSED CARBACHOL, INHIBITION 
OF MEPC HEIGHT, AND CALCULATED REDUCTION IN FREE RECEPTORS BY 
dTC 
Response (percent control) 
Calculated percent reduction 
in free receptors 
Test  40 nM dTC  100 nM dTC  40 nM dTC  100 nM dTC 
10/~M carbachol  53•  (11)  31•  (10)  47•  69• 
20 p,M carbachol  54•  (12)  34•  (11 )  46•  66• 
MEPCs 
AChE intact  80•  (7)  64•  (19)  50•  70• 
AChE poisoned  88•  (8)  72:t:4  (8)  52:t:15  75• 
Control responses to superperfused carbachol were:  10/xM, AG/G ,,~ 0.132 •  0.005  (71  observations); 20 
#M,  AG/G  --  0.344  •  0.022  (22  observations).  In  each  case  AG/G  was  derived  from  the  observed 
depolarization using the formula given in Methods; with the carbachol tests, the percent reduction in free 
receptors was calculated simply as equal to percent reduction ofl~G/G (see text). For MEPCs, the percent 
reduction in free receptors was calculated from Eq.  5b, using 5.35 nA as the value of g=. All values •  1 
SEM. Number of observations in parentheses. 
In  principle,  by  any  model  of  the  antagonist-receptor  interaction,  the 
response (conductance change) to a given dose ofagonist is simply proportional 
to the fraction of receptors that are not occupied and thereby blocked by the 
antagonist.  When  the  concentration  of the  agonist  is  low  relative  to  its 
dissociation  constant,  i.e.,  when the  measured response  occurs with  only a 
small fraction of receptors occupied by the agonist, the fraction of receptors 
occupied by the antagonist  will  be virtually the same as in  the absence of 
agonist. 
Fig. 7 shows a typical result; depolarizing responses to locally superperfused 
carbachol  (10 or 20/xM)  were substantially reduced by 40 nM dTC, which 
had little effect on the amplitude of MEPPs. Average data are shown in Table 
II; these data are consistent with the same occupancy of receptors by dTC as 
calculated from the effect of dTC on MEPC height. The average slope of the PENNEFATHER AND  O~UASTEL  Receptor Blockade and MEPCs  333 
log-log plot  of AG/G vs. carbachol  concentration  (over the range  5-40 jaM) 
was  1.50 :l: 0.07  in the absence of dTC and was not significantly altered  by 
dTC. 
In  diaphragms  from  animals  treated  with  IgG  from  myasthenia  patients 
the  slope of the  log-log plot  of AG/G vs.  carbachol  concentration  and  the 
apparent  potency of dTC to depress responses to carbachol were the same as 
in control diaphragms. 
In a  few experiments, ACh was used as well as carbachol after poisoning of 
ACHE:  the potency of dTC  to reduce responses to ACh  was the same as its 
potency to reduce responses to carbachol. 
0.04  #M  dTC 
MEPPS~t  ll,  I  !  li  i[  :t  [L,i  .  ,  [  J,i  !,  ,,  ,t  !IlL 
10  carb  20  carb  20  carb  10  carb 
FIGURE  7.  Inhibition of postsynaptic depolarizing responses to superperfused 
carbachol (10 and 20 #M) by 40 nM dTC (right)--responses are about one-half 
the controls (left). MEPPs recorded just after these tests of carbachol sensitivity 
are shown above; there was no noticeable depression of size by the 40-nM dTC. 
Time scales:  1 s per division. 10 mM K + present. There was no change of resting 
membrane potential in the 5 min allowed for equilibration with dTC. 
DISCUSSION 
The principal  results of this study may be summarized very briefly. In mouse 
diaphragms,  the  potency  of  (+)-tubocurarine  (dTC)  in  depressing  MEPC 
amplitude  is  substantially  reduced  by  poisoning  of  acetylcholinesterase 
(ACHE). Even when AChE is intact, the potency is much less than the potency 
ofdTC to depress responses to superperfused carbachol. The effect of  poisoning 
AChE to increase the peak amplitude of MEPCs is normally rather small  (as 
in the snake  [Hartzell  et al.,  1975];  or rat  [Colquhoun et al.,  1977]), but the 
percentage increase is made greater when MEPCs are reduced in size by dTC 
or by pretreatment  of animals  with a-bungarotoxin  (0l-BuTX)  or IgG  from 334  THE  JOURNAL  OF  GENERAL  PHYSIOLOGY- VOLUME  78"  1981 
patients with myasthenia gravis, both of which appear irreversibly to diminish 
effective receptor  density.  The  effectiveness of AChE  poisoning  to  increase 
MEPC  size  appears  to  be  the  same  when  MEPCs  are  made  small  by the 
irreversible  (or  very slowly reversible)  blockers  as  when  MEPCs  are  made 
small  by dTC.  The  last  observation makes it clear that  the enhanced  effec- 
tiveness of AChE poisoning when MEPCs are made small  (Fig. 2) is not to be 
explained  in  terms  of displacement  of blockers  from  the  receptor sites by a 
transient  high  concentration  of ACh  in  the  synaptic  cleft.  Moreover,  the 
apparent  potency of dTC to depress MEPCs is increased when MEPCs have 
already been reduced in size by a-BuTX or IgG from myasthenia patients. 
All  the  above  results  are  explained  quite  simply  if  it  is  supposed  that 
normally the subsynaptic receptor density and onward rate constants for ACh 
to combine with  receptor to form a  relatively stable conformation  are suffi- 
ciently  high  that  most  of the  ACh  in  a  quantal  package  quickly  becomes 
captured  by receptors.  From  examination  of various  models  (Theory),  this 
explanation  remains  valid whatever the intricacies  of ACh-receptor  interac- 
tion. The MEPC is normally insensitive to receptor blockade simply because 
when  ACh  encounters  blocked receptors,  the ACh  is  able to diffuse further 
away from the point of its release, eventually to encounter and be captured by 
unblocked receptors.  Only when  receptor density is  reduced  to the  point  at 
which the rates of ACh loss from the cleft by hydrolysis and diffusion become 
much  larger  than  the  rate  of attachment  to  receptor  will  MEPC  height 
become close to proportional to effective receptor density. Poisoning of AChE 
has normally little effect on MEPC height  merely because normally  most of 
the  ACh  in  the  package  becomes attached  to  receptor  even when  AChE  is 
intact.  When the density of functional receptors has been reduced, there is a 
lower efficiency of capture; poisoning of AChE permits ACh to diffuse further, 
to encounter and be captured by unblocked receptors, and MEPC amplitude 
is  thereby  more  greatly  enhanced.  In  terms  of the  schematic  view  of the 
distribution of activated receptor at the peak of the MEPC shown by Hartzell 
et  al.  (1975),  the  effect of receptor blockade  is  to  reduce  the  height  and  to 
increase the spatial spread; this arises not only because the peak height occurs 
later, but because the net rate of diffusion of transmitter  is faster when most 
receptor sites are occupied, by transmitter  as well as by antagonist.  It may be 
noted  that  near  the  point  where  the  quantum  of transmitter  is  released 
activatable  receptors  must  be  nearly  saturated;  this  is  a  general  feature  of 
models in which the transmitter diffuses from a point source and much of the 
transmitter  becomes bound to receptor (cf.  Matthews-Bellinger  and Salpeter 
[1978]; Wathey et al.  [1979]; Adams [1980]; Land et al.  [1980]). 
It should be emphasized that the above interpretation  of the data does not 
depend upon any assumptions regarding the mode of interaction of dTC with 
receptor or upon the assumption that dTC dissociates slowly from the receptor. 
Nor does it depend on any assumption that the action of IgG from myasthenia 
patients  (or  a-BuTX)  consists  solely  of simple  irreversible  blockade  of the 
receptors.  For  example,  the  same  interpretation  would  hold  if  IgG  from 
patients  with myasthenia  were to act  to prevent  the conformational  change 
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complex  rather  than  to  prevent  access of ACh  to  binding  sites;  this  would 
explain  the relatively prolonged  time-course of "myasthenic"  MEPCs  (after 
AChE poisoning), in relation to the extent of apparent  receptor blockade (cf. 
Table I  and Fig. 6).  However, it is evident  that  a  reduced binding  (either in 
extent  of duration)  of ACh  by those receptors  that  are  rendered  inactive  is 
fundamental  to  the  enhanced  effect of AChE  poisoning  to  increase  MEPC 
height,  found  with  dTC,  ~t-BuTX,  and  IgG  from  myasthenia  patients.  A 
blockade in which inactivated receptors bound ACh in the same way as active 
ones would simply result in reduction of MEPC height, with no alteration of 
time constants or of potency of dTC, or change in effect of AChE poisoning. 
The relation between MEPC height and fraction of receptors free to respond 
to ACh can be inferred from the present data and is shown in Fig. 8. Here the 
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FIGURE 8.  Relation between peak height of MEPCs (at  -80 mV)  and  func- 
tional receptor density, as percentage of normal. Open symbols, AChE intact; filled 
symbols, after poisoning of AChE by paraoxon. Symbols as in Fig.  5. The point 
for the a-BuTX-treated  diaphragm  is superimposed on the value for 4-d IgG 
from myasthenia patients, after paraoxon. Lines drawn according to Eq. 2, with 
gm=  5.3  nA and fl/a  inferred  from  observed IC50  for dTC  in  control  dia- 
phragms. 
extent  of receptor blockade at  various concentrations  of dTC  was obtained 
using  Eq.  5 b and  a  value of 5.1  nA for gm.  The  degree of blockade with  et- 
BuTX and IgG from myasthenia patients are derived from the observed IC50s 
for dTC in these diaphragms  (Theory)  and not directly from MEPC height. 336  THE  JOURNAL  OF  GENERAL  PHYSIOLOGY  ￿9 VOLUME  78  ￿9  1981 
With the latter agents, as with dTC, the percentage receptor blockade is of 
course  not  necessarily synonymous with  percentage occupancy of receptor 
sites.  If,  for example, there are two receptor sites per receptor, occupied at 
random by a-BuTX  (or IgG from myasthenia patients)  then,  if x  were the 
fraction of sites occupied, (1 -  x) 2 would be the fraction of receptors with no 
receptor site occupied and still  capable  of responding to  ACh.  This  model 
would give a  nearly linear relation between height of MEPC and fraction of 
binding sites occupied by toxin  (Ito et al.,  1978;  Land et al.,  1980;  see also 
Albuquerque et al. [1973]). 
In man the plasma concentration of dTC that results in partial paralysis is 
between 0.4 and 0.8 #g/ml or 0.6 and  1.1  #M  (Stanski et al.,  1979;  see also 
Wingard and Cook [ 1978]).  From the present data, a concentration of 0.8 #M 
would be expected to produce an MEPC of one-fifth the normal amplitude, 
which corresponds to  the reduction in  size of MEPPs  observed in  biopsied 
muscle  from  myasthenia  gravis  patients  with  partial  muscular  paralysis 
(Elmqvist et al.,  1964).  From the present results it is evident that to achieve 
this 80% reduction in size and to cause marginal paralysis, all but 5% of the 
receptors must be blocked. In the presence of receptor blockade poisoning of 
AChE becomes less able to prolong the MEPC (Fig. 6), but the reduced effect 
on time-course is countered to a certain extent by the larger effect to increase 
MEPC  size.  Because the relatively low time constant of a  muscle fiber the 
height of an MEPP is about proportional to the area of a  MEPC, it follows 
that  the  effect  of an  anticholinesterase  to  increase  height  of MEPPs  (as 
opposed to MEPCs) may be much the same with or without receptor blockade. 
In both situations the augmenting effect of the anticholinesterase arises solely 
from blockade of AChE but the mechanism is somewhat different. Normally, 
the augmentation arises mainly from repetition of ACh action in the cleft, i.e., 
increased "reverberation" (Katz and Miledi, 1973 a), but when most receptors 
are blocked, poisoning of AChE also allows ACh to diffuse further from its 
source to encounter and to act upon unblocked receptors before being lost to 
the system. 
Our estimate of the fraction of total ACh bound to receptors at the peak of 
the MEPC  (92%  after AChE  is  poisoned)  is  considerably greater than  the 
value of ~50%  for the fraction of cleft ACh apparently bound to receptors 
during the decay phase of the MEPC, also after AChE poisoning, as deduced 
from the acceleration of MEPC  or end-plate current  (EPC)  decay rate by 
receptor blockade  (this paper;  see also Katz  and Miledi,  [1973a];  Magleby 
and  Terrar  [1975];  Colquhoun  et  al.  [1977]).  One  may  doubt  that  the 
difference in  ACh  binding  at  different stages  of the  MEPC  is  so  great  in 
reality, given the approximations inherent in both of the estimates. Neverthe- 
less,  it  is  interesting  to  note  that  a  nearly  constant  degree  of binding  is 
predicted only if there is  no cooperation in ACh-receptor interaction. With 
simple,  sequential  models  in  which  two  receptor  (R)  subunits  have  equal 
affinity for ACh,  but  where the opening of channels  is  associated with  an 
isomerization  of ACh2R  to  a  form,  ACh2R*,  which  dissociates  relatively 
slowly, i.e., 
L 
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the fraction of total ACh that is free at equilibrium, in a closed system, is 
[ACh]/[ACh  d  --  {1  +  2[Rd[ACh  ] 
￿9  (1 +  K[ACh] +  K[ACh]L)/[(1 + K[ACh]) 2 +  Kz[ACh]2L]} -1, 
where [ACh]  denotes concentrations. When  L  >> 0,  this  function increases 
rather than decreases with  falling  [ACht]  (except near receptor saturation). 
Thus, the fraction of total ACh bound to receptors can decrease as the MEPC 
decays  and  the  concentration  of ACh  in  the  cleft  goes  down.  Eventually 
"buffering" of ACh in the cleft will be governed by unproductive ACh binding 
with a dissociation constant of K "-1. Since the density of ACh receptor sites on 
the postsynaptic membrane (~3  ￿  10-4//~m  2)  corresponds to an Rt of ~0.5 
mM (Fambrough and Hartzell,  1972;  Fertuck and Salpeter,  1974 and  1976; 
Wathey et  al.,  1979),  if there are two sites  per receptor a  limiting fraction 
bound of 50%  (when [ACht] and [ACh] are low) corresponds to a  K -1 of ~ 1 
raM. This is much greater than the apparent dissociation constant for ACh, 
~30/~M,  for its action to open ionic channels (Sakmann and Adams,  1978; 
Adams,  1980;  Sakmann et al.,  1980), implying that L  is indeed large or that 
there is  positive cooperation  in  ACh  binding  before the isomerization step 
(which does not change the argument). To account for rapidly rising MEPCs, 
the  onward  rate  constant  for combination  of ACh  with  receptor must  be 
_> 10  -7 M -~ ￿9  s  -1 and is probably ~ l0  s M -1 ￿9  s  -1 (cf. Rosenberry [ 1979];  Wathey 
et  al.  [1979]).  If K -1  is  --.1 mM,  this  gives  an  offward  rate  constant  for 
unproductive binding of ACh of ~10/ms or  100/ms--10 or 100 times faster 
than the rate of closing of channels. The similar affinity of receptor for dTC 
in terms of peak MEPC size (Figs. 4, 5) and in terms of ACh buffering during 
MEPC decay (Fig. 6) suggests that the identical receptors are involved. 
If the above reasoning is correct, the relatively small fraction of ACh bound 
to  receptor during  the  decay phase  of the  MEPC  (after AChE  poisoning) 
reflects both cooperativity in ACh-receptor binding associated with channel 
opening,  and a  relatively faster rate of dissociation of ACh  from the labile 
ACh-receptor complex(es) not associated with an open channel. In terms of 
physiological function, these factors will minimize trapping of  ACh by receptor 
in the labile forms normally before channel opening and permit efficient use 
of ACh after its release without producing a  signal that is greatly prolonged 
relative to the duration of the ionic channels. At the same time, a premium is 
put  on  the high concentration of transmitter in  the cleft immediately after 
presynaptic discharge of a  quantum--the "competition" of AChE and recep- 
tor for the transmitter will favor receptor binding when ACh first enters the 
cleft  but  will  favor hydrolysis when the concentration of ACh  in  the cleft 
becomes low. Also, nonquantal "leak" of ACh from the nerve terminal (Katz 
and Miledi, 1977; Vyskofiil and Illes, 1977; Vizi and Vysko~il, 1979) will cause 
little postsynaptic response. 
The mode of interaction of dTC with receptors is not critical to the present 
results or to the conclusions that have been presented, but it is notable that 
three different actions of dTC--the effect on MEPC size, the effect on MEPC 
time-course  (when AChE  is  poisoned),  and  the effect on  responses  to  car- 
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of receptor (or binding site) blockade by dTC. From the degree of blockade, 
it is possible to ascribe a value for the KI (dissociation constant) for dTC only 
if a specific model of dTC-receptor interaction is chosen. Reported values for 
the KI of dTC in mammalian muscle, based on shifts of dose-response curves 
are close to  100 nM (Lu,  1970;  Waud et al.,  1973;  Walker and Yeoh,  1974). 
The dose-ratio method (see below) employed by these investigators requires 
the  assumption  of one-to-one  competition  of antagonist  with  agonist.  If 
channel opening usually requires the "cooperation" of two molecules of ACh, 
for which there is very persuasive evidence (e.g., Sheridan and Lester [1977]; 
Dreyer et  al.  [1978]),  this  is  tantamount  to  the assumption  that  two  dTC 
molecules can combine with the receptor and with this model the present data 
give a  value of between 100 and  150 nM for the KI for dTC. 
Nevertheless, our present data suggest that the degree of receptor blockade 
by dTC is linearly, rather than parabolically, related to dTC concentration 
(see  Fig.  4).  This  agrees with  the observation  of Goldsmith  (1963)  that  at 
concentrations of dTC considerably above its apparent KI,  the amplitude of 
end-plate potentials (EPPs) (in frog) was inversely related to the dTC concen- 
tration, rather than to the square of dTC concentration. These results fit most 
easily to a model in which only one dTC molecule can attach to the receptor, 
i.e., there is only one binding site per receptor (in which case the K1 is  ~40 
nM) or there are two binding sites but binding to one site excludes binding to 
another (in which case the KI is ~80 nM if both sites have the same aft~nity). 
Either of these models predicts, however, that  the classical method for esti- 
mating antagonist  afffinity--measurement of the shifts  of dose-response for 
agonist  produced by various concentrations of antagonists  (Gaddum,  1937; 
Arunlakshana and Schild,  1959;  see also Colquhoun et al.  [1979])-- should 
show that the dose-ratio (DR, the factor by which agonist concentration must 
be raised to compensate for the antagonist) is not linearly related to antagonist 
concentration. If n molecules of agonist "cooperate" to activate a receptor but 
one antagonist molecule is sufficient to block the receptor, then it should be 
DR  n -  1 rather than DR -  1 that is proportional do [dTC].  However, such 
studies  with  dTC  generally show  a  good  fit  to  linearity  (Jenkinson,  1960; 
Rang and Ritter,  1969;  Parker and Goldfine,  1973;  Walker and Yeoh,  1974; 
Adams,  1975b)  in  mammalian  as well  as  in  amphibian  and  avian  muscle. 
Indeed, the data of Colquhoun et al.  (1979)  show that the fit to a one-to-one 
ratio of dTC-agonist competition becomes even better after correction for the 
secondary action of dTC, to block open ionic channels (Manalis,  1977;  Katz 
and Miledi,  1978). 
Thus, results obtained from studies using equilibrium responses to cholin- 
ergic agonists lead to a model of dTC-receptor interaction different from that 
obtained from MEPCs (present data) or EPPs (Goldsmith, 1963).  It is possible 
that this discrepancy can be accounted for in terms of different affinities for 
dTC of the two binding sites  (purified rat junctional receptors [Brockes and 
Hall, 1975];  Torpedo electric organ membrane fragments [Weiland and Taylor, 
1979;  Neubig and Cohen,  19791; cultured myoblasts [Sine and Taylor,  1979; 
1980]).  Such a  model specifies for f(1)  a  value of 
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where K1 and/(2 are the two dissociation constants. A/(2 of 1 #M, together 
with a K1 of 50 nM, is within experimental error for the relation between f(I) 
and [dTC] shown in Fig. 4, and predicts a  dose-ratio estimate of (K1K2)l/2 of 
-200  nM,  which is  at  the upper limit compatible with published  data  for 
mammalian receptors (Waud and Waud,  1975).  The close-to-linear relation 
between  the  inverse of EPP  height  and  [dTC]  in  the  range  1-10  /~M,  as 
observed by Goldsmith (1963) in the frog, can fit this model only if K2 is -10 
/~M;  this  is  difficult to  reconcile with  the data of Colquhoun  et  al.  (1979). 
Another possibility is complexity in dTC (and ACh) interaction with receptor. 
For example, if there are four binding sites per receptor (Khromov-Borisov 
and Michelson,  1966;  Miller et al.,  1978), one may postulate that a  channel 
can be opened (with stabilization of the agonist-receptor complex) by agonist 
occupancy of any two of these sites. If attachment of dTC to one or even two 
of the sites does not prevent receptor activation (channel opening) but merely 
reduces the probability, it would also explain the observation of Sheridan and 
Lester (1977),  subsequently confirmed by Colquhoun  and  Sheridan  (1979), 
that the transition between closed and open channel states is slowed by dTC 
(although not by a-BuTX)  without having to postulate "astonishingly fast" 
association  and  dissociation  of dTC.  We  find, using computer synthesis of 
MEPCs  (Theory),  that  it  is  indeed  possible  with  such  a  model  to  obtain 
MEPCs for which the inverse of MEPC height is very nearly linear with dTC 
concentration, as we observe (and observed for EPPs by Goldsmith  [1963]), 
whereas  equilibrium  responses  to  agonist  in  the  presence of dTC  fit  very 
closely to what would be expected for a one-to-one competition of dTC with 
agonist. Further description and discussion of this (rather complicated) model 
will be presented elsewhere. 
In apparent  contradiction to the present  results, Goldsmith  (1963)  found 
that  responses  to  70-ms  iontophoretic  pulses  of ACh  were less  sensitive  to 
increases in the concentration of dTC than were EPPs recorded at the same 
junction. This can be explained as follows. In the case of the EPP or MEPP, 
there can be little net dissociation of dTC from receptor during the very short 
time of rise of the synaptic conductance. However, with a  long iontophoretic 
pulse  of ACh,  a  high  concentration  of ACh  is  maintained  locally  for  a 
relatively long time during which there is effective displacement of dTC by 
the agonist.  In  support  of this  view, brief iontophoretic pulses  gave rise to 
responses that were more similar to EPPs in their sensitivity to dTC than were 
responses to long iontophoretic pulses (Goldsmith,  1963).  In conformity with 
the present results, Adams (1975b)  has reported that, in the frog, responses to 
iontophoretic pulses of carbachol are less sensitive to blockade by dTC than 
are the responses to bath application of carbachol, and pointed out that from 
the work of Auerbach and Betz (197 I) the MEPP and EPP size in frog is even 
less  sensitive  to  dTC.  The  explanation  of this  phenomenon  suggested  by 
Adams (1975 b) is essentially the same as the one we have adopted. 
The data of Albuquerque et al. (1980) also show differences in sensitivity to 
dTC of responses to exogenous and endogenous ACh; reduced MEPC height 
to 44% of control and reduced the response produced by a  30-s iontophoretic 
pulse of ACh to 25% of control. A  much greater difference in sensitivity was 340  THE  JOURNAL  OF  GENERAL  PHYSIOLOGY  ￿9  VOLUME  78  ￿9  1981 
observed  when  perhydrohistrionicotoxin  was  used  as  an  antagonist;  such  a 
large  difference  cannot  be  explained  on  the  same  basis  as  the  difference 
observed  with  dTC  and  suggests  receptor  heterogeneity.  Because  perhydro- 
histrionicotoxin  potentiates  the  desensitization  process  (Burgermeister et  al., 
1977)  the  receptor  heterogeneity  may  have  been  generated  by nonuniform 
distribution  of iontophoresed  ACh  over the receptor area  (see Miledi,  1980), 
i.e.,  normal-size  MEPCs  may  have  been  generated  outside  the  region  of 
desensitization. 
In conclusion,  it may be noted  that  a  nonlinear  relation  between effective 
receptor  density  and  response to  endogenous  quantal  transmitter  is implicit 
wherever the receptor density and rate of binding are such that normally most 
of the  transmitter  becomes  captured  by  receptor.  It  follows  that  at  many 
synapses, responses to exogenous (or circulating)  transmitter substance should 
be  more sensitive  to  receptor  blockade  than  the  responses  produced  by  the 
same transmitter when it is released by the nerve terminal. 
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